Análise das notificações de eventos atribuíveis à vacinação ou imunização das vacinas do covid-19 em Goiânia, Goiás, Brasil

Abstract

Introduction: The pandemic caused by the SARS-Cov-2 virus, which causes the disease COVID-19, caused a high socioeconomic impact in just a few months, a sharp increase in the incidence of deaths, complications and irreversible damage to the clinical picture of the affected population, giving rise to the need for emergency use of immunobiologicals. In Brazil, the use of the AstraZeneca and CoronaVac vaccines was initially approved. Every vaccine is likely to cause adverse reactions, therefore it is essential to report possible post-vaccination adverse events. Objective: to analyze the ESAVI reported for the AstraZeneca and CoronaVac vaccines in the year of implementation of the vaccination schedule in the National Immunization Program (PNI). Methodology: A descriptive cross-sectional study was carried out, using information present in the secondary database originating from the E-SUS Notifica platform. The data was categorized by key variables, and subsequently statistically analyzed, using Excel Office 16. Results: 0.036% of vaccine doses administered in 2021 were reported under suspicion of ESAVI. The majority of notifications were made by women aged between 36 and 49 years. Health professionals also contributed by reporting ESAVI to health authorities. However, pregnant women were the smallest (priority) group who presented and/or reported any possible adverse reactions. Conclusion: It can be concluded that the majority of ESAVI reported were not serious, with a cure outcome without sequelae, showing that vaccination is still the best way to reduce the impacts caused by viruses.